



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Loren J. Field, et al.

Serial No.: 10/024,066

Filed: December 18, 2001

CARDIOMYOCYTES WITH ENHANCED
PROLIFERATIVE POTENTIAL, AND

METHODS FOR PREPARING AND USING SAME) December 20, 2005

) Before the Examiner

) Daniel M. Sullivan

)

) Group Art Unit

) 1636

)

)

)

)

)

INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97, and 1.98, Applicant requests consideration of the references listed on the attached PTO/SB/08 forms and/or the additional information identified below.

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Mailing Label No. EV746141074US, on the date indicated below.

John J. Emmons, Jr.

Typed/printed name of person signing this certificate

December 20, 2005
Date

[Signature]
Signature

12/23/2005 DTESSEH1 00000071 10024066

02 FC:1806

180.00 0P

Information Disclosure Statement

Serial No. 10/024,066

Group Art Unit 1636

Attorney Dkt. No. 7037-450

Page 1 of 2


#377286

A legible copy of each foreign patent document and publication listed on the PTO/SB/08 form is enclosed.


This information Disclosure Statement is submitted after three months from the filing date and after the first Office Action on the merits, but prior to the mailing date of a final Office Action or Notice of Allowance, and thus a fee of \$180.00 (set forth in 37 CFR §1.17(p)) is enclosed. The Commissioner is hereby authorized to debit any additional fee or credit any overpayment to Deposit Account No. 23-3030, but not to include any payment of issue fees.

The filing of this Information Disclosure Statement shall not be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in §1.56(b).

Respectfully submitted,

By: 

John J. Emanuele, Jr., Ph.D. J.D., Reg. No. 51,653
Woodard, Emhardt, Moriarty, McNett & Henry LLP
111 Monument Circle, Suite 3700
Indianapolis, Indiana 46204-5137
(317) 634-3456- telephone
(317) 637-7561- facsimile



PTO/SB/08A (09-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/024,066
				Filing Date	12/18/2001
				First Named Inventor	Loren J. Field
				Group Art Unit	1636
				Examiner Name	Daniel M. Sullivan
Sheet	1	of	4	Attorney Docket Number	7037-450
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
		5,688,665	11-18-1997	Massague et al	
		5,821,234	10-13-1998	Dzau	
		5,869,640	02-09-1999	Beach	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (09-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		10/024,066	
				Filing Date		12/18/2001	
				First Named Inventor		Loren J. Field	
				Group Art Unit		1636	
				Examiner Name		Daniel M. Sullivan	
Sheet	2	of	4	Attorney Docket Number		7037-450	
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite ¹ No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ²	Number ³ Kind Code ⁴ (if known) ⁵				
		WO 99/49015	A2	09-30-1999	Zymogenetics, Inc.		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/024,066		
		Filing Date	12/18/2001		
		First Named Inventor	Loren J. Field		
		Group Art Unit	1636		
		Examiner Name	Daniel M. Sullivan		
Sheet	3	of	4	Attorney Docket Number	7037-450
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published			T²
		ALT ET AL, "Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation", Genes & Development, 2000, Vol./Issue No. 14, pp. 3102-3114, Cold Springs Harbor Laboratory Press			<input type="checkbox"/>
		BENZENO ET AL, "C-terminal Sequences Direct Cyclin D1-CRM1 Binding", The Journal of Biological Chemistry, 2004, Vol./Issue No. 279/53, pp. 56061-56066			<input type="checkbox"/>
		BROOKS, GAVIN ET AL., "Expression and Activities of Cyclins and Cyclin-Dependent Kinases in Developing Rat Ventricular Myocytes", Jnl Molecular & Cellular Cardiology, 1997, Vol./Issue No. 29/8, pp. 2261-2271			<input type="checkbox"/>
		DIEHL ET AL, "A Dominant-Negative Cyclin D1 Mutant Prevents Nuclear Import of Cyclin-Dependent Kinase 4 (CDK4) and Its Phosphorylation by CDK-Activating Kinase", Molecular and Cellular Biology, Dec. 1997 Vol./Issue No. 17/12 pp. 7362-7374			<input type="checkbox"/>
		DIEHL ET AL, "Glycogen synthase kinase-3 β regulates cyclin D1 proteolysis and subcellular localization", Genes & Development, 1998, Vol./Issue No. 12, pp. 3499-3511, Cold Springs Harbor Laboratory Press			<input type="checkbox"/>
		FUKUDA ET AL., "Angiotensin II Potentiates DNA Synthesis in AT-1 Transformed Cardiomyocytes", J Mol Cell Cardiol, 1998, Vol./Issue No. 30, pp. 2069-2080, Academic Press			<input type="checkbox"/>
		GERMAIN ET AL, "Ubiquitination of Free Cyclin D1 Is Independent of Phosphorylation on Threonine 286", The Journal of Biological Chemistry, 2000, Vol./Issue No. 275/16, pp. 12074-12079			<input type="checkbox"/>
		HAUK ET AL, "E2F-1 Induces Cell Cycle Reentry in Cardiomyocytes through Release of k1p1/cip cdk Inhibitors", Circulation, 10-27-1998, Vol./Issue No. 98/17 Suppl., pp. I 262			<input type="checkbox"/>
		HOLLYOAKE ET AL, "The Normal Cell Cycle Activation Program is Exploited During the Infection of Quiescent B Lymphocytes by Epstein-Barr Virus", Cancer Research, 11-01-1995, Vol./Issue No. 55, pp. 4784-4787			<input type="checkbox"/>
		KATZ, E. ET AL., "Cardiomyocyte Proliferation in Mice Expressing γ -Cardiac Myosin Heavy Chain-SV40 T-Antigen Transgenes", Am. J. Phys. (Heart and Circulatory Physiology 31), 1992, Vol./Issue No. 262 pp. 1867-1876			<input type="checkbox"/>
		KIYOKAWA, HIROAKI ET AL, "Cloning of D-type Cyclin from Murine Erythroleukemia Cells", Proc. Natl. Acad. Sci. USA, March 1992, Vol./Issue No. 89, Cell Biology, pp. 2444-2447			<input type="checkbox"/>
		MCEWAN ET AL., "Differential Effects of Angiotensin II on Cardiac Cell Proliferation and Intramyocardial Perivascular Fibrosis In Vivo", Circulation, 1998, Vol./Issue No. 98, pp. 2765-2773			<input type="checkbox"/>
		NOMURA, N., ET AL., "Human mRNA for KIAA0076 Gene, Complete CDS, Database EMBL 'Online', Retrieved from EBI, November 3, 1994, Vol./Issue No. EBI Database Accession No. D38548, abstract			<input type="checkbox"/>
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/024,066
				Filing Date	12/18/2001
				First Named Inventor	Loren J. Field
				Group Art Unit	1636
				Examiner Name	Daniel M. Sullivan
Sheet	4	of	4	Attorney Docket Number	7037-450
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published			T²
		SWEENEY ET AL., "Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells, Oncogene, 1997, Vol./Issue No. 14, pp. 1329-1340, Stockton Press			<input type="checkbox"/>
		TAMAMORI ET AL., "Essential Roles for G1 Cyclin-Dependent Kinase Activity in Development of Cardiomyocyte Hypertrophy", Am. Jnl. of Physiology, December 1998, Vol./Issue No. 275 (6Pt.2), pp. H2036-H2040			<input type="checkbox"/>
		TSAI, SHIH-CHONG, "Tumor Suppressor Pathway in Myocardium (RAD50, Phosphoproteins)", Dissertation Abstracts International, February 1999, AAD99-19502, Vol./Issue No. Figures 1D and 1E, pp. 190-193, Michigan			<input type="checkbox"/>
		TSAI, SHIH-CHONG ET AL., "Simian virus 40 large T antigen binds a novel Bcl-2 homology domain 3-containing proapoptosis protein in the cytoplasm.", Journal of Biological Chemistry, February 4, 2000, Vol./Issue No. Vol. 275, No. 5, pp. 3239-3246			<input type="checkbox"/>
		XIONG ET AL., "Molecular Cloning and Chromosomal Mapping of CCND Genes Encoding Human D-type Cyclins", Genomics, 1992, Vol./Issue No. 13, pp. 575-584			<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.